Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (3): 221-225.DOI: 10.3969/j.issn.1673-8640.2022.03.006
Previous Articles Next Articles
FAN Weiguang1, SU Miaomiao2, MENG Juan2, SHI Penghui1(), ZHANG Zhen2
Received:
2021-04-13
Revised:
2021-12-09
Online:
2022-03-30
Published:
2022-05-10
Contact:
SHI Penghui
CLC Number:
FAN Weiguang, SU Miaomiao, MENG Juan, SHI Penghui, ZHANG Zhen. Changes and clinical significance of IP-10 for antiviral therapy in AIDS patients[J]. Laboratory Medicine, 2022, 37(3): 221-225.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.03.006
组别 | 例数 | CD4+T细胞/% | CD8+T细胞/% | IP-10/(pg/mL) |
---|---|---|---|---|
AIDS组 | 200 | 25.25±3.26 | 34.27±4.12 | 1 786.25±257.61 |
正常对照组 | 100 | 43.86±4.62 | 17.64±1.45 | 85.17±35.47 |
t值 | 36.005 | 41.496 | 65.669 | |
P值 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | CD4+T细胞/% | CD8+T细胞/% | IP-10/(pg/mL) |
---|---|---|---|---|
AIDS组 | 200 | 25.25±3.26 | 34.27±4.12 | 1 786.25±257.61 |
正常对照组 | 100 | 43.86±4.62 | 17.64±1.45 | 85.17±35.47 |
t值 | 36.005 | 41.496 | 65.669 | |
P值 | <0.001 | <0.001 | <0.001 |
时间点 | CD4+T细胞/% | CD8+T细胞/% | IP-10/(pg/mL) | HIV-1 RNA/(lg拷贝/mL) | HIV-1抑制/[例(%)] |
---|---|---|---|---|---|
治疗前 | 25.25±3.26 | 34.57±4.12 | 1 786.25±257.61 | 4.62±0.73 | 0(0) |
治疗后 | |||||
2周 | 26.47±3.35* | 33.23±4.25* | 1 427.85±227.35* | 3.45±0.42* | 5(2.50) |
1个月 | 27.82±3.41* | 32.84±3.96* | 1 294.57±196.47* | 2.94±0.37* | 16(8.00) |
2个月 | 28.64±3.52* | 30.45±3.83* | 1 137.39±157.40* | 2.64±0.32* | 31(15.50)* |
3个月 | 29.12±3.63* | 29.49±3.69* | 967.39±125.67* | 2.34±0.17* | 107(53.50)* |
6个月 | 30.47±3.92* | 28.65±3.15* | 829.45±84.63* | 1.84±0.15* | 161(80.50)* |
12个月 | 31.84±4.32* | 26.14±2.75* | 653.52±47.38* | 1.12±0.11* | 185(92.50)* |
18个月 | 33.27±4.27* | 25.47±2.64* | 526.28±42.74* | 0.84±0.08* | 191(95.50)* |
时间点 | CD4+T细胞/% | CD8+T细胞/% | IP-10/(pg/mL) | HIV-1 RNA/(lg拷贝/mL) | HIV-1抑制/[例(%)] |
---|---|---|---|---|---|
治疗前 | 25.25±3.26 | 34.57±4.12 | 1 786.25±257.61 | 4.62±0.73 | 0(0) |
治疗后 | |||||
2周 | 26.47±3.35* | 33.23±4.25* | 1 427.85±227.35* | 3.45±0.42* | 5(2.50) |
1个月 | 27.82±3.41* | 32.84±3.96* | 1 294.57±196.47* | 2.94±0.37* | 16(8.00) |
2个月 | 28.64±3.52* | 30.45±3.83* | 1 137.39±157.40* | 2.64±0.32* | 31(15.50)* |
3个月 | 29.12±3.63* | 29.49±3.69* | 967.39±125.67* | 2.34±0.17* | 107(53.50)* |
6个月 | 30.47±3.92* | 28.65±3.15* | 829.45±84.63* | 1.84±0.15* | 161(80.50)* |
12个月 | 31.84±4.32* | 26.14±2.75* | 653.52±47.38* | 1.12±0.11* | 185(92.50)* |
18个月 | 33.27±4.27* | 25.47±2.64* | 526.28±42.74* | 0.84±0.08* | 191(95.50)* |
时间点 | 例数 | CD4+T细胞/% | CD8+T细胞/% | IP-10/(pg/mL) |
---|---|---|---|---|
治疗后3个月 | ||||
HIV-1抑制组 | 107 | 33.35±4.15 | 26.57±3.17 | 816.98±96.54 |
HIV-1未抑制组 | 93 | 27.82±3.52 | 30.39±3.20 | 1 013.58±124.37 |
t值 | 9.020 | 7.174 | 9.949 | |
P值 | <0.001 | <0.001 | <0.001 | |
治疗后6个月 | ||||
HIV-1抑制组 | 161 | 32.72±3.96 | 27.13±3.22 | 729.14±82.35 |
HIV-1未抑制组 | 39 | 24.17±2.87 | 34.95±3.41 | 1 243.34±134.26 |
t值 | 12.690 | 13.452 | 30.472 | |
P值 | <0.001 | <0.001 | <0.001 | |
治疗后12个月 | ||||
HIV-1抑制组 | 185 | 32.37±3.75 | 25.53±3.13 | 608.01±74.36 |
HIV-1未抑制组 | 15 | 25.32±2.94 | 33.67±3.17 | 1 214.86±126.52 |
t值 | 7.100 | 9.678 | 28.547 | |
P值 | <0.001 | <0.001 | <0.001 | |
治疗后18个月 | ||||
HIV-1抑制组 | 191 | 33.68±3.42 | 25.18±3.15 | 492.97±58.64 |
HIV-1未抑制组 | 9 | 24.55±3.05 | 31.71±3.25 | 1 231.35±131.47 |
t值 | 7.859 | 6.070 | 34.236 | |
P值 | <0.001 | <0.001 | <0.001 |
时间点 | 例数 | CD4+T细胞/% | CD8+T细胞/% | IP-10/(pg/mL) |
---|---|---|---|---|
治疗后3个月 | ||||
HIV-1抑制组 | 107 | 33.35±4.15 | 26.57±3.17 | 816.98±96.54 |
HIV-1未抑制组 | 93 | 27.82±3.52 | 30.39±3.20 | 1 013.58±124.37 |
t值 | 9.020 | 7.174 | 9.949 | |
P值 | <0.001 | <0.001 | <0.001 | |
治疗后6个月 | ||||
HIV-1抑制组 | 161 | 32.72±3.96 | 27.13±3.22 | 729.14±82.35 |
HIV-1未抑制组 | 39 | 24.17±2.87 | 34.95±3.41 | 1 243.34±134.26 |
t值 | 12.690 | 13.452 | 30.472 | |
P值 | <0.001 | <0.001 | <0.001 | |
治疗后12个月 | ||||
HIV-1抑制组 | 185 | 32.37±3.75 | 25.53±3.13 | 608.01±74.36 |
HIV-1未抑制组 | 15 | 25.32±2.94 | 33.67±3.17 | 1 214.86±126.52 |
t值 | 7.100 | 9.678 | 28.547 | |
P值 | <0.001 | <0.001 | <0.001 | |
治疗后18个月 | ||||
HIV-1抑制组 | 191 | 33.68±3.42 | 25.18±3.15 | 492.97±58.64 |
HIV-1未抑制组 | 9 | 24.55±3.05 | 31.71±3.25 | 1 231.35±131.47 |
t值 | 7.859 | 6.070 | 34.236 | |
P值 | <0.001 | <0.001 | <0.001 |
[1] | 任其奎, 孙其玉, 田兆菊, 等. 白细胞介素-32在病毒感染性疾病中的作用研究进展[J]. 中华医院感染学杂志, 2019, 29(4):636-640. |
[2] |
PALSTRA R J, DE CRIGNIS E, RÖLING M D, et al. Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1[J]. Sci Adv, 2018, 4(2):e1701729.
DOI URL |
[3] |
ARCHIN N M, SUNG J M, GARRIDO C, et al. Eradicating HIV-1 infection:seeking to clear a persistent pathogen[J]. Nat Rev Microbiol, 2014, 12(11):750-764.
DOI URL |
[4] | 胡艮娣, 王晓泉, 陈祥, 等. 趋化因子IP-10在介导病毒感染性疾病中的研究进展[J]. 病毒学报, 2019, 35(4):672-678. |
[5] |
CERVANTES-BARRAGÁN L, FIRNER S, BECHMANN I, et al. Regulatory T cells selectively preserve immune privilege of self-antigens during viral central nervous system infection[J]. J Immunol, 2012, 188(8):3678-3685.
DOI URL |
[6] | SANTOS V S, GOLETTI D, KONTOGIANNI K, et al. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis:systematic review and meta-analysis[J]. Clin Microbiol Infect, 2019, 25(2):169-177. |
[7] | 张福杰. 国家免费艾滋病抗病毒药物治疗手册[M]. 北京: 人民卫生出版社, 2012. |
[8] |
BROWNELL J, POLYAK S J. Molecular pathways:hepatitis C virus,CXCL10,and the inflammatory road to liver cancer[J]. Clin Cancer Res, 2013, 19(6):1347-1352.
DOI URL |
[9] | 董海平, 刘志辉, 梁小成, 等. 血浆干扰素诱导蛋白10在不同受累范围肺结核患者血浆中的表达[J]. 南方医科大学学报, 2019, 39(5):609-613. |
[10] |
QIU X, XIONG T, SU X, et al. Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis[J]. BMC Infect Dis, 2019, 19(1):924.
DOI URL |
[11] |
LEE S, CHUNG Y S, YOON C H, et al. Interferon-inducible protein 10(IP-10) is associated with viremia of early HIV-1 infection in Korean patients[J]. J Med Virol, 2015, 87(5):782-789.
DOI URL |
[12] |
PASTOR L, CASELLAS A, RUPÉREZ M, et al. Interferon-γ-inducible protein 10(IP-10) as a screening tool to optimize human immunodeficiency virus RNA monitoring in resource-limited settings[J]. Clin Infect Dis, 2017, 65(10):1670-1675.
DOI URL |
[13] |
PUJANTELL M, BADIA R, RAMIREZ C, et al. Long-term HIV-1 infection induces an antiviral state in primary macrophages[J]. Antiviral Res, 2016, 133:145-155.
DOI URL |
[14] |
JIAO Y, ZHANG T, WANG R, et al. Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection[J]. Viral Immunol, 2012, 25(4):333-337.
DOI URL |
[15] |
NOEL N, LEROLLE N, LÉCUROUX C, et al. Immunologic and virologic progression in HIV controllers:the role of viral "Blips" and immune activation in the ANRS CO21 CODEX study[J]. PLoS One, 2015, 10(7):e0131922.
DOI URL |
[16] |
ROE B, COUGHLAN S, HASSAN J, et al. Elevated serum levels of interferon-gamma-inducible protein-10 in patients coinfected with hepatitis C virus and HIV[J]. J Infect Dis, 2007, 196(7):1053-1057.
DOI URL |
[17] |
LIOVAT A S, REY-CUILLÉ M A, LÉCUROUX C, et al. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection[J]. PLoS One, 2012, 7(10):e46143.
DOI URL |
[18] |
NOEL N, BOUFASSA F, LÉCUROUX C, et al. Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients[J]. AIDS, 2014, 28(4):467-476.
DOI URL |
[19] |
RAMIREZ L A, ARANGO T A, THOMPSON E, et al. High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART[J]. J Leukoc Biol, 2014, 96(6):1055-1063.
DOI URL |
[20] |
PELTENBURG N C, SCHOEMAN J C, HOU J, et al. Persistent metabolic changes in HIV-infected patients during the first year of combination antiretroviral therapy[J]. Sci Rep, 2018, 8(1):16947.
DOI URL |
[21] |
PASTOR L, URREA V, CARRILLO J, et al. Dynamics of CD4 and CD8 T-cell subsets and inflammatory biomarkers during early and chronic HIV infection in Mozambican adults[J]. Front Immunol, 2018, 8:1925.
DOI URL |
[1] | ZHAO Jing, LI Yongqin, LI Yan, FAN Weiguang, YANG Xuegang. Roles of IP-10,SAA,hs-CRP,PCT and CD4+ T cell count determinations in HIV/AIDS patients with opportunistic infection [J]. Laboratory Medicine, 2023, 38(8): 725-729. |
[2] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
[3] | LU Xinli, LIU Yong, LI Yan, WANG Yingying, AN Ning, LIU Meng. Identification of near full-length genome structures of new HIV-1 recombinant strains [J]. Laboratory Medicine, 2023, 38(11): 1015-1019. |
[4] | SUN Qi, QU Xinyi, XU Li. Analysis on outcome of patients with indeterminate western-blot results of HIV-1 antibody [J]. Laboratory Medicine, 2022, 37(8): 741-744. |
[5] | WANG Wanhai, MENG Zhen, YANG Ruonan, GAO Nan, WANG Qingfang, ZHANG Lei, WANG Meifen, MING Liang. Analysis of common patterns of HIV antibody banding by western blotting and its role in follow-up period [J]. Laboratory Medicine, 2020, 35(2): 95-99. |
[6] | LIU Yixuan, GUO Lin, LU Renquan. Research progress of AIDS related lymphoma diagnosis and treatment [J]. Laboratory Medicine, 2020, 35(2): 173-177. |
[7] | SUN Bin, WANG Shan, QIAN Jun, TANG Zhenhua. Prenatal screening for 63 109 pregnant women in Shanghai [J]. Laboratory Medicine, 2017, 32(5): 386-389. |
[8] | WEI Shanqiu. Research progress on immune factors related with HIV infectious disease development [J]. Laboratory Medicine, 2015, 30(6): 646-649. |
[9] | GUO Chuan, JI Linying, WU Yaobo, LIN Jiemin, CHEN Wan. The band patterns of Western blotting in different clinical stages of HIV-1 infection/AIDS patients [J]. Laboratory Medicine, 2015, 30(2): 145-148. |
[10] | XIAO Minmin,WANG Yi,SHAO Hui,ZHANG Yan,LI Ping. Investigation of HCV co-infection among HIV-1 infected patients in the South of Anhui [J]. , 2014, 29(7): 705-707. |
[11] | WANG Peng 1,XIAO Qing 2,TAI Shuhong 1,YANG Simei 2,XUE Ximei 2,SONG Junhua 3,JIA Liting 1. The infection of hepatitis C virus and treponema pallidum among HIV single-infection couples in Queshan county [J]. , 2013, 28(2): 137-139. |
[12] | LI Bo;GU Dayong;SITU Bo;LI Zhengliang;YAN Xiaohui;LIU Qinlan;ZHENG Lei;WANG Qian. The construction and confirmation of HIV-1 electrochemically active–inactive switching molecular beacon [J]. , 2012, 27(5): 408-411. |
[13] | ZHANG Haiyan;WANG Wanhai;XIA Xueshan;WANG Yongheng;FENG Yue;SU Tianrong;ZHANG Xiaoyan. Investigation of HCV co-infection among HIV-1 infected patients in Dali city [J]. , 2012, 27(2): 141-144. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||